Moderna, Inc.Cambridge, Massachusetts, United States
Disclosure information not submitted.
90 - Interim Assessment of Safety and Immunogenicity From a Proof-of-Concept Phase 2 Trial of an mRNA-Based Cytomegalovirus Vaccine in Patients Who Have Undergone Allogeneic Hematopoietic Cell Transplantation
Monday, October 20, 202511:30 AM - 11:43 AM US ET
